PMID- 20490358
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20211203
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2010
DP  - 2010
TI  - The effect of chronic candesartan therapy on the metabolic profile and renal 
      tissue cytokine levels in the obese Zucker rat.
PG  - 841343
LID - 10.1155/2010/841343 [doi]
LID - 841343
AB  - The effect of candesartan, an angiotensin-II type-1 receptor antagonist, on the 
      metabolic profile and renal inflammation is unclear. We evaluated this 
      relationship by feeding male lean (LZ) and obese (OZ) Zucker rats chow or chow 
      with candesartan (23.5 mg/kg . diet) for 14 weeks (n = 6-8/treatment/body type). 
      Candesartan reduced serum triglycerides, plasma creatinine, urine albumin, and 
      renal cortical collagen and glycogen deposition in the OZ. An ELISA-based 
      cytokine array revealed that candesartan normalized elevated renal interleukin 
      (IL) 1-beta and monocyte chemoattractant protein-1 (MCP-1) levels in OZ. 
      Nonetheless, candesartan impaired glucose tolerance, and did not lower blood 
      insulin or glucose levels. Moreover, renal IL-1alpha, -2, -4, -6 and -10 tumor 
      necrosis factor-alpha, interferon-gamma, were significantly reduced in OZ 
      relative to LZ, and increased by candesartan. Furthermore, candesartan increased 
      growth-regulated oncogene, transforming growth factor-beta1 and IL-18 in OZ 
      kidneys to a level higher than LZ or untreated OZ. Candesartan did not affect 
      renal cytokine levels in LZ. Overall, candesartan attenuated renal disease and 
      improved renal function in OZ, despite mixed effects on metabolic factors and 
      cytokines. Reduced plasma triglycerides and/or renal MCP-1 and IL-1beta may have 
      had a role in this protection. However, these effects were clearly independent of 
      any improvement in glucose tolerance.
FAU - Ecelbarger, Carolyn M
AU  - Ecelbarger CM
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Georgetown 
      University, Washington, DC 20057, USA.
FAU - Rash, Arjun
AU  - Rash A
FAU - Sinha, Rajesh K
AU  - Sinha RK
FAU - Tiwari, Swasti
AU  - Tiwari S
LA  - eng
GR  - R01 HL073193/HL/NHLBI NIH HHS/United States
GR  - HL073193/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100517
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Cytokines)
RN  - 0 (Tetrazoles)
RN  - S8Q36MD2XX (candesartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Animals
MH  - Benzimidazoles/*therapeutic use
MH  - Biphenyl Compounds
MH  - Cytokines/*metabolism
MH  - Diet
MH  - Humans
MH  - *Kidney/metabolism/pathology/physiopathology
MH  - *Kidney Diseases/drug therapy/pathology/physiopathology
MH  - Male
MH  - Metabolic Syndrome/metabolism/physiopathology
MH  - Obesity/metabolism/physiopathology
MH  - Rats
MH  - Rats, Zucker
MH  - Tetrazoles/*therapeutic use
PMC - PMC2872766
EDAT- 2010/05/22 06:00
MHDA- 2010/08/18 06:00
PMCR- 2010/05/17
CRDT- 2010/05/22 06:00
PHST- 2009/10/02 00:00 [received]
PHST- 2010/01/27 00:00 [revised]
PHST- 2010/03/05 00:00 [accepted]
PHST- 2010/05/22 06:00 [entrez]
PHST- 2010/05/22 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
PHST- 2010/05/17 00:00 [pmc-release]
AID - 10.1155/2010/841343 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2010;2010:841343. doi: 10.1155/2010/841343. Epub 2010 May 17.